PE20170248A1 - El control efectivo y eficaz del fosfato serico para una osificacion optima - Google Patents
El control efectivo y eficaz del fosfato serico para una osificacion optimaInfo
- Publication number
- PE20170248A1 PE20170248A1 PE2016002698A PE2016002698A PE20170248A1 PE 20170248 A1 PE20170248 A1 PE 20170248A1 PE 2016002698 A PE2016002698 A PE 2016002698A PE 2016002698 A PE2016002698 A PE 2016002698A PE 20170248 A1 PE20170248 A1 PE 20170248A1
- Authority
- PE
- Peru
- Prior art keywords
- fgf23
- seq
- ligand
- effective
- seric
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title 1
- 230000011164 ossification Effects 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 6
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 abstract 3
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 abstract 1
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 abstract 1
- 208000029663 Hypophosphatemia Diseases 0.000 abstract 1
- 210000001766 X chromosome Anatomy 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003553 hypophosphatemic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001132—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se refiere a un metodo para utilizar un ligando anti-FGF23 (factor de crecimiento de fibroblastos 23) que comprende administrar a un sujeto que lo necesita una cantidad efectiva de un ligando anti-FGF23, donde el regimen de dosificacion del ligando se determina en funcion de uno o mas parametros farmacodinamicos (PD) del ligando en el sujeto. El ligando anti-FGF23 se selecciona de anticuerpos anti-FGF23, oligonucleotidos antisentido de FGF23, inhibidores de molecula pequena de FGF23 y antagonistas FGF23; dicho ligando comprende una o mas secuencias CDR de SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 o SEQ ID NO: 4, SEQ ID NO: 5 y SEQ ID NO: 6; siendo util en el tratamiento de un trastorno hipofosfatemico tal como hipofosfatemia ligada al cromosoma X (XLH)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462009474P | 2014-06-09 | 2014-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20170248A1 true PE20170248A1 (es) | 2017-04-14 |
Family
ID=54769049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016002698A PE20170248A1 (es) | 2014-06-09 | 2015-05-29 | El control efectivo y eficaz del fosfato serico para una osificacion optima |
Country Status (23)
Country | Link |
---|---|
US (4) | US10639360B2 (es) |
EP (2) | EP3845245A1 (es) |
JP (2) | JP6808493B2 (es) |
KR (2) | KR20170013993A (es) |
CN (1) | CN106604743A (es) |
AR (1) | AR100689A1 (es) |
AU (1) | AU2015275128C1 (es) |
BR (2) | BR112016028567A2 (es) |
CA (1) | CA2949234C (es) |
CL (1) | CL2016003179A1 (es) |
CY (1) | CY1124328T1 (es) |
DK (1) | DK3151859T3 (es) |
ES (1) | ES2851674T3 (es) |
HR (1) | HRP20210250T1 (es) |
HU (1) | HUE053271T2 (es) |
LT (1) | LT3151859T (es) |
MX (2) | MX2016016296A (es) |
PE (1) | PE20170248A1 (es) |
PL (1) | PL3151859T3 (es) |
PT (1) | PT3151859T (es) |
RS (1) | RS61443B1 (es) |
SI (1) | SI3151859T1 (es) |
WO (1) | WO2015191312A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2348114T3 (en) | 2004-04-21 | 2018-09-03 | Alexion Pharma Inc | BONE DELIVERY CONJUGATES AND PROCEDURE TO USE IT FOR TARGETING PROTEINS AGAINST BONE |
CA2949234C (en) | 2014-06-09 | 2022-03-22 | Ultragenyx Pharmaceutical Inc. | Anti-fgf23 antibody for treatment of hypophosphatemic disorders |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
MX2018002121A (es) | 2015-08-17 | 2018-06-18 | Alexion Pharma Inc | Elaboracion de fosfatasas alcalinas. |
WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN |
WO2017173413A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
WO2017173395A1 (en) * | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 気管気管支軟化症の治療方法 |
CN106709662B (zh) * | 2016-12-30 | 2021-07-02 | 山东鲁能软件技术有限公司 | 一种电力设备运行工况划分方法 |
CN110719786A (zh) | 2017-03-31 | 2020-01-21 | 阿雷克森制药公司 | 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法 |
US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
AU2005202100A1 (en) | 1999-05-11 | 2005-06-09 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
EP2345742B1 (en) | 2000-03-30 | 2014-06-11 | The Whitehead Institute for Biomedical Research | RNA sequence-specific mediators of RNA interference |
AU7332301A (en) | 2000-07-19 | 2002-02-05 | Advanced Res & Tech Inst | Novel fibroblast growth factor (FGF23) and methods for use |
ATE469217T1 (de) | 2000-08-11 | 2010-06-15 | Kyowa Hakko Kirin Co Ltd | Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle |
KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
KR101016476B1 (ko) * | 2001-12-28 | 2011-02-24 | 교와 핫꼬 기린 가부시키가이샤 | 섬유아세포 증식 인자-23에 대한 항체 |
US8158725B2 (en) | 2005-08-22 | 2012-04-17 | Bridgestone Corporation | Functionalized polymers and tires therefrom |
US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
WO2012050673A1 (en) | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
CA2949234C (en) | 2014-06-09 | 2022-03-22 | Ultragenyx Pharmaceutical Inc. | Anti-fgf23 antibody for treatment of hypophosphatemic disorders |
-
2015
- 2015-05-29 CA CA2949234A patent/CA2949234C/en active Active
- 2015-05-29 US US14/725,320 patent/US10639360B2/en active Active
- 2015-05-29 WO PCT/US2015/033226 patent/WO2015191312A1/en active Application Filing
- 2015-05-29 ES ES15806501T patent/ES2851674T3/es active Active
- 2015-05-29 MX MX2016016296A patent/MX2016016296A/es unknown
- 2015-05-29 EP EP20208220.2A patent/EP3845245A1/en active Pending
- 2015-05-29 CN CN201580039280.XA patent/CN106604743A/zh active Pending
- 2015-05-29 HU HUE15806501A patent/HUE053271T2/hu unknown
- 2015-05-29 SI SI201531522T patent/SI3151859T1/sl unknown
- 2015-05-29 PT PT158065011T patent/PT3151859T/pt unknown
- 2015-05-29 DK DK15806501.1T patent/DK3151859T3/da active
- 2015-05-29 EP EP15806501.1A patent/EP3151859B1/en active Active
- 2015-05-29 BR BR112016028567A patent/BR112016028567A2/pt not_active Application Discontinuation
- 2015-05-29 KR KR1020177000293A patent/KR20170013993A/ko not_active Application Discontinuation
- 2015-05-29 KR KR1020217024284A patent/KR20210099180A/ko not_active IP Right Cessation
- 2015-05-29 PE PE2016002698A patent/PE20170248A1/es unknown
- 2015-05-29 LT LTEP15806501.1T patent/LT3151859T/lt unknown
- 2015-05-29 RS RS20210173A patent/RS61443B1/sr unknown
- 2015-05-29 AR ARP150101715A patent/AR100689A1/es unknown
- 2015-05-29 BR BR122023023102-3A patent/BR122023023102A2/pt unknown
- 2015-05-29 PL PL15806501T patent/PL3151859T3/pl unknown
- 2015-05-29 AU AU2015275128A patent/AU2015275128C1/en active Active
- 2015-05-29 JP JP2016569651A patent/JP6808493B2/ja active Active
-
2016
- 2016-12-08 MX MX2021003740A patent/MX2021003740A/es unknown
- 2016-12-09 CL CL2016003179A patent/CL2016003179A1/es unknown
-
2020
- 2020-03-26 US US16/831,179 patent/US11202822B2/en active Active
- 2020-12-09 JP JP2020204298A patent/JP6993490B2/ja active Active
-
2021
- 2021-02-12 HR HRP20210250TT patent/HRP20210250T1/hr unknown
- 2021-02-23 CY CY20211100154T patent/CY1124328T1/el unknown
- 2021-11-12 US US17/525,738 patent/US11771748B2/en active Active
-
2023
- 2023-08-07 US US18/366,447 patent/US20240115683A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20170248A1 (es) | El control efectivo y eficaz del fosfato serico para una osificacion optima | |
MX2020003901A (es) | Composiciones y metodos para modular la expresion del receptor de la hormona del crecimiento. | |
EA201790926A1 (ru) | Комбинированное лечение злокачественного новообразования | |
EA201990848A1 (ru) | ЗАМЕЩЕННЫЕ 1H-ИМИДАЗО[4,5-b]ПИРИДИН-2(3H)-ОНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GLUN2B | |
EA201992474A3 (ru) | Агонисты 5ht для лечения нарушений | |
CL2018000649A1 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx / ca | |
MX2017008218A (es) | Anticuerpos anti-csf1r para tratar pvns. | |
CU20190067A7 (es) | Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr) | |
MX2022011281A (es) | Npp1 para usarse en el tratamiento de calcificacion de tejidos. | |
CU20190069A7 (es) | Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr) | |
FR2975600B1 (fr) | Agents pour le traitement de tumeurs | |
MX2014013950A (es) | Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras. | |
EA201790643A1 (ru) | Способ и устройство для непрерывного нанесения нанослоистых металлических покрытий | |
BR112015033069A2 (pt) | moduladores de receptor do hormônio de crescimento | |
MX2017000142A (es) | Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. | |
PE20130815A1 (es) | Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos | |
BR112018012913A2 (pt) | tratamento in situ de sementes em sulco | |
EA201500670A1 (ru) | Egfr-направленная терапия неврологических нарушений и боли | |
MX2016009314A (es) | Sistemas generadores de impulso electrico que utilizan acoplamiento capacitivo. | |
WO2015158890A3 (en) | Pancreatic cancer therapy and diagnosis | |
EA201691702A1 (ru) | Химерные белки мти | |
BR112016029460A2 (pt) | métodos para tratar artrite reumatoide | |
PH12016502150A1 (en) | Method for treating renal cell carcimona | |
GB201103780D0 (en) | Treatment for ige-mediated disease | |
EA201291210A1 (ru) | Композиция для ухода за волосами |